Abstract
The aim of the given work was study interactions of impairments sympathetic – adrenal systems functional condition and processes of peroxidal oxidation of lipids in woman with metabolic syndrome. 107 women at the age of 25-49 were observation. They were randomized into 3 groups: I (control) – 15 healthy persons, II – 43 patients with arterial hypertension, III – 49 women with arterial hypertension in combination with metabolic syndrome.
The results of carried investigations showed that activation of sympathetic adrenal system and processes of peroxidal oxidation of lipids took place in metabolic syndrome. Marked lowering of sympathetic – adrenal system key ferment catecholamins (MAO monoaminooxidaze) desalinization activity and considerable activation of peroxidal oxidation of lipid products which have great significance in revealing the mechanism of metabolic syndrome development were observed in metabolic syndrome. This results in the prolonged toxic influence of catecholamine on myocardium.
References
Almazov V., Blagosklonnaya Ya., Gilyakhto E., Krasilnikova E. Metabolic cardiovascular syndrome. // St. Petersburg: SPBSMU Publishing House, 1999, pp. 23-25.
Alyavi A. L., Mirkhaitova N. A., Tulyaganova D. K., Shodiev Zh. D. Condition of patients with arterial hypertension with metabolic syndrome. // Res. Scientific and practical conference 2008. P. 42.
Vasiliev V. N., Chugunov V. S. Sympathetic-adrenal activity in various functional states of a person.M. Meditsina; 1985.272.
Mamedov M. N. Metabolic syndrome: practical aspects of diagnosis and treatment in outpatient settings. Manual for doctors. Moscow; 2005.6-33.
Mamedov M. N. Arterial hypertension in the framework of the metabolic syndrome: features of the course and principles of drug correction. Kardiologiya 2004; No. 4. 95-100.
Ogonov R. G., Perova N. V., Shcheltsina N. V. et al. Manifestations of the metabolic syndrome in combination with arterial hypertension and individual coronary risk factors.
Kardiologiya 2005.№7.27-33.
Stryuk R. I., Tsyganok N. Yu.Neurohumoral mechanisms of metabolic syndrome pathogenesis. Kardiologiya 2006; 4: 54-58.
Sokolov E. I., Simonenko V. B., Zykova A. A., Srednyakov A.V. Clinical significance of insulin resistance detection in women with metabolic syndrome. Kardiologiya 2006; 4: 24-29.
Khuzhamberdiev M. A. On disorders and ways of normalization of biogenic amine metabolism in atherosclerosis and coronary heart disease. Dissertation of Doctor of Medical Sciences, Moscow. 1985.
Chazova I. E., Mychka V. B., Kislyak O. A., Kuznetsova I. V., Shestakova M. V. Diagnosis and treatment of metabolic syndrome. //Companies in Russia. 2009. pp. 105-144.
Chibisov S. M., Rapoport S. I., Kolesnikov D. B., Loboda A. Y. Metabolic syndrome: more questions than answers. Klinicheskaya meditsina; No. 6. 2008. 30-35.
Bagdade J.D., Buchanan W.F., Pollare T.,Lithell H.Abnormal lipoprotein phospholidip composition in patients with essential hypertension. Atherosclerosis 1995:117:209-215.
Esler M.. Rumanier.. Wiesner G. et al. Sympathetic nervous system and insylin resistance. From obesite to diabetes. Am. J. Hypertens. 2001.14: 304-309.
Giordano M., Matsuda M., Sanders L. et al. Effects of angiotensinconverting enzyme inhibitors. Ca channel antagonists and adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995.44. 665-671.
Tashtemirova I.M., Uzbekova N.R., Kodirova G.I. Disturbances of mao activity and in the processoflipid peroxide oxidation in patients, who underwentcoronary aortal bypass grafting and coronary stent fixing and their corrections